Prestige Consumer Healthcare Inc. PBH
Spruce Point is short Prestige Brands: a decaying OTC roll-up with no organic growth, CFO déjà-vu from Boulder Brands' collapse, and 40-60% downside to $14.80-$22.50.
Thesis
Spruce Point is short Prestige Brands, a $3.5bn roll-up of orphaned OTC healthcare products (PediaCare, Dramamine, Compound W), arguing 40-60% downside to $14.80-$22.50/share. The thesis: PBH has compounded only 1% organic revenue growth over six years while missing its own targets 4 of 5 years, and now faces intensifying private-label competition from Walmart Equate and CVS store brands that erodes pricing power and shelf placement. CFO Christine Sacco, hired from Boulder Brands — which collapsed 50% after Spruce Point's 2013 short — has made three stealth revenue-disclosure changes mirroring Boulder's pre-collapse playbook, and brought three Boulder lieutenants with her. Cash conversion cycle has ballooned from 67 to 110 days, DSOs from 48 to 57, and aggressive non-GAAP adjustments mask GAAP declines. Spruce Point calls for CEO Ron Lombardi and CFO Sacco to resign and the audit committee to investigate financial reporting practices.
SCQA
Prestige Brands is a $3.5bn consumer healthcare roll-up owning orphaned OTC brands (PediaCare, Dramamine, Compound W, Fleet, DenTek) sold through Walmart, CVS and Amazon, marketed by management as a steady-growth, recession-resistant free-cash-flow compounder.
Organic growth has averaged 1% over six years, private-label store brands are stealing share, and CFO Christine Sacco — formerly of the collapsed Boulder Brands — has quietly altered revenue disclosures exactly as she did pre-Boulder's implosion, while working capital and cash conversion deteriorate.
CEO Ron Lombardi and CFO Sacco should resign, the audit committee must investigate financial reporting and accounting practices, and management must reset guidance lower and take further goodwill and intangible asset impairments.
Applying an 8-9x FY2022 EBITDA multiple (vs consensus 12.9x) yields a $14.80-$22.50 target price, representing 40-60% downside from the $36.63 share price at publication.
The three reasons
- 1
Organic revenue compounded only 1% over 6 years with no pricing power vs private-label Walmart/CVS brands
- 2
CFO Sacco's stealth revenue-disclosure changes mirror her playbook at Boulder Brands, which collapsed 50%
- 3
Ballooning DSOs, cash conversion cycle and aggressive non-GAAP adjustments signal earnings decline ahead
Primary demands
- CEO Ron Lombardi and CFO Christine Sacco should resign
- Audit committee must conduct a full investigation into financial reporting and accounting practices
- Management must reset expectations lower and take additional asset impairments
- Improve revenue and segment disclosure to peer-standard levels
KPIs cited
Pattern membership
Precedents cited
- Boulder Brands short (Prescience Point, 2013) — CFO Sacco's prior employer collapsed 50%
- Caesarstone short (Spruce Point, 2015) — two CEOs and two CFOs resigned, shares fell >70%
- iRobot short (Spruce Point, 2018-2019) — disappointing sales growth, CFO transition
- Church & Dwight short (Spruce Point, 2019) — disappointing Q3, Chief Accounting Officer retired
- B&G Foods SEC Comment Letter as disclosure precedent
Composition what's on the 122 slides
Slide gallery ·
Notes
Classic Spruce Point short-report template: teal/grey institutional look with text-heavy slides and annotated charts. Signature rhetorical moves present — (1) opens with editorial cover image (rat and roaches next to laxative/enema products as visual metaphor for 'sinking ship'), (2) track-record slide (pg 3) arguing authority by citing four prior successful shorts: Boulder Brands, Caesarstone, iRobot, Church & Dwight, (3) side-by-side 'Boulder Brands vs Prestige Brands' checklist (pg 13) as playbook analogy with CFO Christine Sacco as common thread, (4) Glassdoor employee quote ('Prestige is a buyout firm... products and brands get bought to come here to die'), (5) analyst-quote contradiction (DA Davidson calling PBH 'recession resistant' paired against company's 2020 proxy admitting they cannot set credible 1-3 year goals). No stake disclosure — Spruce Point discloses only that they are short. Framing is adversarial but analytical, not litigious; no fraud allegation per se but strong accounting and disclosure concerns with explicit CEO/CFO resignation ask.